| 1 |
NCT02414425 |
Recruiting |
Effect and Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence |
|
- Procedure: Rectoscopy
- Procedure: Anorectal manometry
- Drug: Botulinum toxin A or physiologic serum injection
|
Interventional |
Phase 3 |
- University Hospital, Rouen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in the Number of active fecaI incontinence episodes per week
- Change from baseline in the Number of urgencies episodes per week
- Number of Adverse Events
- (and 2 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02414425 |
2014/008/HP
2014-003650-14 |
FI_TOXIN |
December 2015 |
January 2019 |
July 2019 |
April 10, 2015 |
December 7, 2016 |
|
- Bordeaux University Hospital
Bordeaux, France - Clinique des Cèdres
Cornebarrieu, France - Hospices Civils de Lyon
Lyon, France - (and 5 more...)
|
| 2 |
NCT01162525 |
Recruiting |
Percutaneous Tibial Nerve Stimulation for Patients With Fecal Incontinence |
|
- Procedure: Percutaneous tibial nerve stimulation (pTNS)
|
Interventional |
Not Applicable |
- Cantonal Hospital of St. Gallen
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Fecal Incontinence
- Anorectal manometric measurements
- Quality of Life
- (and 3 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01162525 |
pTNS |
|
January 2010 |
October 2017 |
December 2017 |
July 14, 2010 |
July 21, 2017 |
|
- Department of Surgery, Cantonal Hospital St. Gallen
St. Gallen, Switzerland
|
| 3 |
NCT02556151 |
Recruiting |
Neuromodulation Therapy for Fecal Incontinence |
|
- Procedure: Repetitive magnetic stimulation
|
Interventional |
Not Applicable |
- Augusta University
- University of Manchester
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The reduction in number of episodes of Fecal Incontinence
- Bowel symptoms
- Quality of life
- (and 2 more...)
|
48 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02556151 |
1R21DK104127-01 |
|
April 2015 |
March 2018 |
April 2018 |
September 22, 2015 |
January 9, 2018 |
|
- Augusta University
Augusta, Georgia, United States - University of Manchester
Manchester, United Kingdom
|
| 4 |
NCT03216291 |
Recruiting |
Home Versus Office Biofeedback Therapy for Fecal Incontinence |
|
- Behavioral: biofeedback therapy
- Device: Home Biofeedback therapy
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- number of episodes of fecal incontinence
- Squeeze anal sphincter pressure
- Overall quality of life and symptom perception on previously validated Fecal Incontinence questionnaires
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03216291 |
HomeVOfficeFI |
|
October 2015 |
November 2017 |
November 2017 |
July 13, 2017 |
July 13, 2017 |
|
- Augusta University
Augusta, Georgia, United States
|
| 5 |
NCT03261622 |
Recruiting |
Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective |
- Faecal Incontinence
- Fecal Incontinence
|
- Device: Sacral nerve stimulation at different stimulation amplitudes
|
Interventional |
Not Applicable |
- University of Aarhus
- University of Tromso
- Hvidovre University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Bowel Habit Diary changes
- Bowel Habit Diary
- Functional outcome measure - Wexner Incontinence score
- (and 5 more...)
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT03261622 |
005 |
SNS |
November 1, 2016 |
November 1, 2019 |
November 1, 2020 |
August 25, 2017 |
August 25, 2017 |
|
- Anal Physiology Laboratory, Surgical Research Section 900, Aarhus University Hospital
Aarhus, Aarhus C, Denmark
|
| 6 |
NCT02828384 |
Recruiting |
Comparing the Effectiveness of Two Dietary Interventions for Fecal Incontinence |
|
- Other: low fodmap diet
- Dietary Supplement: Psyllium
|
Interventional |
Phase 2 |
- University of Michigan
- The Rome Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Change in number of FI episodes from baseline to week 4
- number of people responding with decreased score in stool consistency
- number of people responding with reduction in stool frequency
- (and 5 more...)
|
40 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02828384 |
00079064 |
|
September 2014 |
July 2018 |
July 2018 |
July 11, 2016 |
June 28, 2017 |
|
- University of Michigan
Ann Arbor, Michigan, United States
|
| 7 |
NCT01600755 |
Recruiting |
Autologous Cell Therapy for Treatment of Fecal Incontinence |
|
|
Interventional |
Phase 1
Phase 2 |
- Cook MyoSite
- Cook Group Incorporated
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-related adverse events
- Frequency of incontinent episodes
- Incontinence score
- (and 2 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT01600755 |
09-025 |
|
May 2012 |
December 2018 |
December 2019 |
May 17, 2012 |
December 2, 2017 |
|
- St. Paul's Hospital
Vancouver, British Columbia, Canada - Royal London Hospital
London, United Kingdom
|
| 8 |
NCT02628626 |
Recruiting |
A Study of Colesevelam in Fecal Incontinence |
- Fecal Incontinence
- Bile Acid Malabsorption
|
- Drug: Colesevelam
- Drug: Clonidine
- Other: Placebo
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage of patients who have a 50% reduction in the frequency of fecal incontinence (FI) episodes
- Change in the number of days with fecal incontinence
- Change in the volume of fecal incontinence
- (and 12 more...)
|
60 |
Female |
18 Years to 80 Years (Adult, Senior) |
NCT02628626 |
15-005986 |
|
November 2015 |
October 2018 |
October 2019 |
December 11, 2015 |
July 21, 2017 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
| 9 |
NCT03492502 |
Not yet recruiting
New |
Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease |
- Fecal Microbiota Transplantation in Graft vs. Host Disease
|
- Biological: Autologous Fecal Microbiota Transplantation
|
Interventional |
Not Applicable |
- Rambam Health Care Campus
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Development of severe adverse events (SAEs) related to autologous FMT
- Complete or partial response of GI-related GVHD after each FMT
- Non-severe adverse events (AE)
- (and 2 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT03492502 |
rambam207 |
|
May 1, 2018 |
April 30, 2019 |
April 30, 2019 |
April 10, 2018 |
April 10, 2018 |
|
- Rambam Health Care Campus
Haifa, Israel
|
| 10 |
NCT02888899 |
Recruiting |
Tibial Nerve Stimulation in Combination With Biofeedback |
|
- Behavioral: Biofeedback
- Drug: Loperamide
- Drug: Stool bulking agent (sterculia or ispaghula husk)
- Other: PTNS
|
Interventional |
Not Applicable |
- University Hospital, Linkoeping
|
Other |
- Primary Purpose: Treatment
|
- Change in fecal leakage episodes with a symptom diary
|
|
All |
18 Years and older (Adult, Senior) |
NCT02888899 |
Dnr 2015/443-31 |
|
March 2016 |
March 2018 |
March 2019 |
September 5, 2016 |
September 5, 2016 |
|
- Pelvic floor unit, University Hospital in Linköping
Linköping, Sweden
|
| 11 |
NCT02778048 |
Not yet recruiting |
BAFIARS - Biomedical Assessment of Function and Imaging of the Ano-rectal Sphincter |
|
- Other: MRI (magnetic resonance imaging)
- Other: US (ultra sound)
- Other: FLIP (functional lumen imaging probe)
- Other: HRAM (high resolution anal manometry)
|
Observational |
|
- University Hospital Inselspital, Berne
- Nano-Tera.ch, Lausanne
- Kantonsspital Winterthur KSW
- (and 2 more...)
|
Other |
- Observational Model: Other
- Time Perspective: Retrospective
|
- sphincter closing pressure [mmHG]
- sphincter muscle length [mm]
- sphincter muscle thickness [mm]
- (and 2 more...)
|
50 |
All |
60 Years and older (Adult, Senior) |
NCT02778048 |
KEK BE 359/15 |
|
June 2018 |
July 2020 |
July 2020 |
May 19, 2016 |
December 13, 2017 |
|
- University Hospital Bern
Bern, Switzerland
|
| 12 |
NCT02913950 |
Not yet recruiting |
Pediatric Bristol Stool Scale |
- Validation of Pediatric Stool Scale
|
- Other: validation of pediatric stool scale
|
Observational |
|
- Universitair Ziekenhuis Brussel
|
Other |
|
- validation of pediatric Bristol stool scale
|
100 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02913950 |
2016-281 |
|
October 2016 |
December 2016 |
December 2017 |
September 26, 2016 |
September 28, 2016 |
|
|
| 13 |
NCT03359980 |
Not yet recruiting |
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer |
- Fecal Microbiota Transplantation
|
- Drug: fecal microbiota transfer
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Efficacy of FMT in the treatment of Steroid Refractory -Gastro-intestinal Acute GVHD (SR-GI-aGVHD) at D28 post inclusion
- Safety of FMT in patients with SR-GI-aGVHD
- Number of patients with infectious disorders
- (and 2 more...)
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT03359980 |
MPOH03 |
HERACLES |
March 2018 |
March 2019 |
September 2019 |
December 2, 2017 |
December 4, 2017 |
|
|
| 14 |
NCT03052946 |
Not yet recruiting |
Bulking Agent Versus Electrostimulation Therapy in Anal Incontinence |
|
- Procedure: Bulking agent
- Procedure: Endoanal electrostimulation
|
Interventional |
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT03052946 |
09082009 |
Bulking |
February 28, 2018 |
November 30, 2019 |
March 30, 2020 |
February 14, 2017 |
February 6, 2018 |
|
|
| 15 |
NCT03014505 |
Recruiting |
Fecal Microbiota Transplantation for Decompensated Cirrhosis |
- Decompensated Cirrhosis
- Fecal Microbiota Transplantation
|
- Biological: FMT
- Other: traditional treatments
|
Interventional |
Phase 1
Phase 2 |
- First Affiliated Hospital of Chengdu Medical College
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of adverse events complication rate in all patients in both groups
- Improvement in liver function test as compared to baseline in both groups.
- Reduction in systemic inflammatory markers like TNF-α in both groups.
- (and 5 more...)
|
60 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03014505 |
FMT-GYH |
FMTDC |
August 2016 |
March 2018 |
July 2018 |
January 9, 2017 |
January 9, 2017 |
|
- IEC of Chengdu Medical College
Chendu, China
|
| 16 |
NCT03029078 |
Recruiting |
FEcal Transplant, a Hope to Eradicate Colonization of Patient Harboring eXtreme Drug Resistant Bacteria? |
- Microbial Colonization
- Bacterial Peritonitis
- Faeces Smearing
|
- Drug: fecal microbiota transplant
|
Interventional |
Phase 4 |
- Centre d'Investigation Clinique et Technologique 805
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Negativation of digestive tract colonization
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03029078 |
GIPIT002
2014-003048-11 |
FEDEX |
November 1, 2014 |
January 1, 2019 |
January 1, 2019 |
January 24, 2017 |
January 24, 2017 |
|
- Hopital Raymond Poincaré
Garches, France
|
| 17 |
NCT03325855 |
Recruiting |
Fecal Microbiota Transplant National Registry |
- Fecal Microbiota Transplantation
- Clostridium Difficile Infection
- Gut Microbiome
|
- Other: None - Observational
|
Observational |
|
- American Gastroenterological Association
- OpenBiome
- University of California, San Diego
- Icahn School of Medicine at Mount Sinai
|
Other / Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- Occurrence of treatment related Adverse Events
- Disease Re-occurrence Following FMT
|
4000 |
All |
Child, Adult, Senior |
NCT03325855 |
AmericanGA |
FMT |
September 20, 2017 |
August 2021 |
August 2026 |
October 30, 2017 |
April 11, 2018 |
|
- Children's Hospital of Los Angeles
Los Angeles, California, United States - Sutter Roseville Medical Center
Roseville, California, United States - Yale New Haven Hospital
Hamden, Connecticut, United States - (and 10 more...)
|
| 18 |
NCT02355834 |
Recruiting |
Faecal Incontinence iNtervention Study |
- Fecal Incontinence
- Inflammatory Bowel Disease (IBD)
|
- Other: IBD nurse intervention
|
Interventional |
Not Applicable |
- London North West Healthcare NHS Trust
- Queen Mary University of London
- King's College London
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- The St Mark's faecal incontinence score (0-24 scale)
- International Consultation on Incontinence - Inflammatory Bowel Disease (ICIQ-IBD)
- Inflammatory Bowel Disease - Quality of Life (IBD-Q)
- (and 8 more...)
|
186 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02355834 |
RD14/042 |
FINS |
May 2015 |
August 2017 |
August 2017 |
February 4, 2015 |
September 27, 2016 |
|
- St. Marks Hospital (London North West Healthcare NHS Trust)
Harrow, London, United Kingdom - Queen Elizabeth II Hospital
King's Lynn, Norfolk, United Kingdom - Bart's Health NHS Trust
London, United Kingdom - (and 3 more...)
|
| 19 |
NCT03350178 |
Recruiting |
Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY |
- Intensive Care Units
- Fecal Microbiota Transplantation
|
- Drug: fecal microbiota transfer
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Occurrence of FMT-related treatment emergent (serious) adverse events
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Occurrence of FMT-related treatment emergent (serious) adverse events as per investigator's opinion
- Evaluation of FMT impact on Multi Drug Resistant Bacteria carriage
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03350178 |
MPICU01 |
HAPY3 |
January 15, 2018 |
May 15, 2018 |
May 15, 2018 |
November 22, 2017 |
February 28, 2018 |
|
- Salengro hospital
Lille, France - Bichat Hospital
Paris, France
|
| 20 |
NCT03125564 |
Recruiting |
FMT for Patients With IBS With Fecal and Mucosal Microbiota Assessment |
- Irritable Bowel Syndrome
- Fecal Microbiota Transplantation
|
- Procedure: Fecal Microbiota Transplantation
- Procedure: Sham
- Procedure: Fecal and Mucosal Microbiota Assessment
|
Interventional |
Not Applicable |
- Chinese University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The proportion of responder
- The proportion of patients who had adequate relief of global IBS symptoms
- Assess the onset and duration of relief of IBS symptoms
- (and 5 more...)
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT03125564 |
FMT-IBS study |
|
April 12, 2017 |
January 2, 2019 |
July 31, 2019 |
April 24, 2017 |
April 24, 2017 |
|
- The Chinese University of Hong Kong
Sha Tin, Hong Kong
|
| 21 |
NCT03214289 |
Recruiting |
Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease |
- Stem Cell Transplant Complications
- Graft Versus Host Disease, Acute
- Fecal Microbiota Transplantation
|
- Biological: Fecal Microbiota Transplantation
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serious adverse events
- Non-serious adverse events
- Gut acute Graft-versus-Host Disease (aGvHD) response.
- (and 2 more...)
|
4 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03214289 |
3822-16-SMC |
|
July 12, 2017 |
July 20, 2019 |
December 20, 2019 |
July 11, 2017 |
April 9, 2018 |
|
- Chaim Sheba Medical Center
Ramat Gan, Israel
|
| 22 |
NCT03018613 |
Recruiting |
Fecal Microbiota Transplantation for Chronic Functional Constipation |
- Chronic Functional Constipation
- Intestinal Bacteria Flora Disturbance
- Fecal Microbiota Transplantation
|
- Other: Fecal Microbiota Transplantation
- Other: Normal Saline
|
Interventional |
Phase 1
Phase 2 |
- First Affiliated Hospital of Chengdu Medical College
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of adverse events complication rate in all patients in both groups
- Mean number of bowel movements per week
- Bristol stool scale
- (and 5 more...)
|
60 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03018613 |
FMT-CFC |
FMTFCFC |
July 2016 |
July 2018 |
July 2019 |
January 12, 2017 |
January 12, 2017 |
|
- IEC of Chengdu Medical College
Chendu, China
|
| 23 |
NCT03278613 |
Recruiting |
Neuromodulation for Accidental Bowel Leakage |
|
|
Interventional |
Not Applicable |
- NICHD Pelvic Floor Disorders Network
- University of Alabama at Birmingham
- University of California, San Diego
- (and 8 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- St. Mark's (Vaizey) Score (PTNS vs. Sham)
- Episodes of fecal incontinence (FI) (PTNS vs. Sham)
- Accidental Bowel Leakage Symptom questionnaire (ABLe) score (PTNS vs. Sham)
- (and 16 more...)
|
359 |
Female |
18 Years and older (Adult, Senior) |
NCT03278613 |
12865-29
2U24HD069031-06
2UG1HD069013-06
5UG1HD041267-18
5UG1HD069010-07
5UG1HD069006-07
5UG1HD041261-17
5UG1HD054214-12
5UG1HD054241-12 |
NOTABLe |
February 9, 2018 |
October 2020 |
October 2020 |
September 11, 2017 |
March 21, 2018 |
|
- The University of Alabama at Birmingham
Birmingham, Alabama, United States - Kaiser Permanente -- Downey
Downey, California, United States - University of California at San Diego, UCSD Women's Pelvic Medicine Center
La Jolla, California, United States - (and 6 more...)
|
| 24 |
NCT03016780 |
Recruiting |
Fecal Microbiota Transplantation for Ulcerative Colitis |
- Ulcerative Colitis
- Intestinal Bacteria Flora Disturbance
- Fecal Microbiota Transplantation
|
- Other: Fecal Microbiota Transplantation
- Other: Normal Saline
|
Interventional |
Phase 1
Phase 2 |
- First Affiliated Hospital of Chengdu Medical College
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events
- Improvement of clinical symptoms of the treatment
- The influence of interleukin-10 after the treatment
- Intestinal mucosal immunity
|
60 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03016780 |
FMT-IBD |
FMTFUC |
July 2016 |
July 2018 |
July 2019 |
January 11, 2017 |
January 11, 2017 |
|
- IEC of Chengdu Medical College
Chendu, China
|
| 25 |
NCT02722707 |
Available |
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX |
|
- Device: magnetic anal sphincter augmentation for fecal incontinence
|
Expanded Access |
|
|
Other |
|
|
|
Female |
18 Years and older (Adult, Senior) |
NCT02722707 |
16-000150 |
|
|
|
|
March 30, 2016 |
August 23, 2017 |
|
- Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
| 26 |
NCT03257332 |
Not yet recruiting |
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Curative Surgery for Rectal Cancer. |
- Rectum Cancer
- Fecal Incontinence
- Quality of Life
- Pelvic Floor Disorders
|
- Procedure: Low Anterior Resection for Rectum Cancer
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Faecal incontinence
- LARS-score
- Anorectal muscle function - Latency
- (and 2 more...)
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03257332 |
EDFI-Cohort |
EDFI-Cohort |
August 21, 2017 |
December 31, 2018 |
December 31, 2020 |
August 22, 2017 |
August 22, 2017 |
|
- Slagelse Hospital
Slagelse, Region Zealand, Denmark
|
| 27 |
NCT02575040 |
Recruiting |
Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel Disease |
- Ulcerative Colitis
- Crohn Disease
- Constipation (Excl Faecal Impaction)
|
- Biological: Fecal microbiota transplantation
|
Interventional |
Phase 3 |
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patients with worsened disease
- Adverse events
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02575040 |
GMMA-Fecal Tx-1 |
|
May 2015 |
May 2017 |
May 2020 |
October 14, 2015 |
October 14, 2015 |
|
- Gulhane Military Medical Academy
Ankara, Turkey
|
| 28 |
NCT03489265 |
Not yet recruiting
New |
Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence |
- Fecal Incontinence
- Accidental Bowel Leakage
- Anal Incontinence
- (and 2 more...)
|
- Drug: Eluxadoline 100 mg
- Other: Placebo
|
Interventional |
Phase 2 |
- University of North Carolina, Chapel Hill
- Allergan
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Run-in days per week with fecal incontinence
- Treatment Period 1 days per week with fecal incontinence
- Treatment Period 2 days per week with fecal incontinence
- (and 13 more...)
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT03489265 |
17-1561
895 |
ELXDFI |
May 2018 |
September 2019 |
March 2020 |
April 5, 2018 |
April 5, 2018 |
|
- University of North Carolina at Chapel Hill School of Dentistry Building
Chapel Hill, North Carolina, United States
|
| 29 |
NCT03015467 |
Recruiting |
Fecal Microbiota Transplantation (FMT) for Severe Acute Pancreatitis(SAP) |
- Acute Pancreatitis
- Intestinal Bacteria Flora Disturbance
- Intestinal Dysfunction
- Fecal Microbiota Transplantation
|
- Other: Fecal Microbiota Transplantation
- Other: normal saline
|
Interventional |
Phase 1
Phase 2 |
- First Affiliated Hospital of Chengdu Medical College
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mortality
- C-reactive protein（CRP）
- Diamine oxidase（DAO）
- (and 2 more...)
|
80 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03015467 |
AM-FMT-SAP |
|
December 2016 |
December 2019 |
March 2020 |
January 10, 2017 |
January 11, 2017 |
|
- IEC of Chengdu Medical College
Chendu, China
|
| 30 |
NCT02318134 |
Recruiting |
Fecal Microbiota Transplantation for Pancreatitis |
- Acute Pancreatitis
- Intestinal Bacteria Flora Disturbance
- Intestinal Dysfunction
- Fecal Microbiota Transplantation
|
- Procedure: Fecal Microbiota Transplantation
- Drug: The traditional treatment
|
Interventional |
Phase 1 |
- The First Affiliated Hospital of Nanchang University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Gastrointestinal Failure score
- The incidence of infectious complications
- The incidence of organ failure
- (and 6 more...)
|
60 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02318134 |
Nanchanguniversity |
FMTP |
August 3, 2017 |
December 2018 |
December 1, 2018 |
December 17, 2014 |
November 17, 2017 |
|
- the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
|
| 31 |
NCT02318147 |
Recruiting |
Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC) |
- Acute Pancreatitis
- Fecal Microbiota Transplantation
- Bacterial Translocation
- Infectious Complications
|
- Procedure: Fecal Microbiota Transplantation
- Drug: The traditional treatment
|
Interventional |
Phase 1 |
- The First Affiliated Hospital of Nanchang University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- The control of infectious complications
- C-reactive protein（CRP）level
- Procalcitionin（PCT）level
- (and 2 more...)
|
60 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02318147 |
NanchanguniversityII |
|
November 2016 |
December 2018 |
December 2018 |
December 17, 2014 |
October 18, 2017 |
|
- the First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
|
| 32 |
NCT03252951 |
Recruiting |
Physical Therapy for Anal Incontinence |
- Anal Incontinence
- Fecal Incontinence
|
- Behavioral: Eccentric Training
- Behavioral: Concentric Training
- Behavioral: Isometric Training
- Behavioral: Biofeedback
|
Interventional |
Not Applicable |
- San Diego State University
- University of California, San Diego
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Length Tension Manometry after 12 weeks
- Change in Muscle Hypertrophy (Ultrasound) after 12 weeks
- Change in FISI score after 12 weeks
|
300 |
Female |
22 Years and older (Adult, Senior) |
NCT03252951 |
141728 |
|
September 1, 2017 |
June 2022 |
June 2022 |
August 17, 2017 |
January 12, 2018 |
|
- University of California San Diego
San Diego, California, United States
|
| 33 |
NCT03080753 |
Recruiting |
Treatment of Anal Incontinence With Intersphincteric Implants |
- Anal Incontinence
- Fecal Incontinence
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Severity of anal incontinence
- Postoperative infection
- Change from baseline in pain scores on the VAS at 3 and 12 months.
|
52 |
All |
18 Years and older (Adult, Senior) |
NCT03080753 |
Sphinkeeper 2017 |
|
October 11, 2017 |
September 2018 |
June 2019 |
March 15, 2017 |
January 26, 2018 |
|
- Skåne University Hospital
Malmo, Sweden
|
| 34 |
NCT03283540 |
Recruiting |
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence |
|
- Procedure: TaTME
- Procedure: TME
|
Interventional |
Not Applicable |
- Case Comprehensive Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- average change in anal resting pressure
- maximum squeeze pressure
- Average intra-balloon pressure
- (and 4 more...)
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT03283540 |
CASE6217 |
|
September 25, 2017 |
July 2018 |
July 2018 |
September 14, 2017 |
September 26, 2017 |
|
- Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 35 |
NCT02636517 |
Recruiting |
Fecal Microbiome Transplant |
- Clostridium Difficile
- Inflammatory Bowel Disease
- Crohn's Disease
- Ulcerative Colitis
|
- Biological: Fecal Microbiota Transplant
|
Interventional |
Not Applicable |
- Children's Hospital of Philadelphia
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with a recurrence of C. difficile (CDI)
|
50 |
All |
3 Years to 21 Years (Child, Adult) |
NCT02636517 |
13-010531 |
|
December 2015 |
December 2023 |
December 2023 |
December 21, 2015 |
January 11, 2018 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 36 |
NCT01790061 |
Recruiting |
Standardized Fecal Microbiota Transplantation for Ulcerative Colitis |
- Bacteria
- Microbiota
- Fecal Microbiota Transplantation
- (and 2 more...)
|
- Procedure: Standardized FMT
- Drug: Traditional treatments
|
Interventional |
Phase 2
Phase 3 |
- The Second Hospital of Nanjing Medical University
- Fourth Military Medical University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of FMT
- Adverse events
|
500 |
All |
6 Years to 80 Years (Child, Adult, Senior) |
NCT01790061 |
FMT-CN-121123 |
|
November 2012 |
December 2022 |
December 2032 |
February 13, 2013 |
January 9, 2018 |
|
- Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
|
| 37 |
NCT02686645 |
Not yet recruiting |
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection |
- Clostridium Difficile Infection
|
- Biological: Fecal Microbiota
- Drug: vancomycin
- Drug: Loperamide
- Drug: metronidazole
|
Interventional |
Phase 2
Phase 3 |
- Queen Elizabeth II Health Sciences Centre
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Resolution of CDI
- Success of treatment
- Adverse effects
- (and 3 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02686645 |
NSHA REB File #: 1020563 |
|
December 2016 |
December 2021 |
December 2021 |
February 19, 2016 |
September 27, 2016 |
|
|
| 38 |
NCT03317938 |
Recruiting |
Studies in Patients With Defecatory Disorders |
- Fecal Incontinence
- Constipation
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Decreased anorectal pressure assessed with the Fecobionics device
- Decreased anorectal mechanical stress assessed with the Fecobionics device
- Decreased anorectal angle assessed with the Fecobionics device
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03317938 |
2017.122 |
|
August 14, 2017 |
August 1, 2018 |
August 1, 2018 |
October 23, 2017 |
October 23, 2017 |
|
- Department of Surgery, Prince of Wales Hospital
Hong Kong, Hong Kong
|
| 39 |
NCT02715141 |
Recruiting |
Molecular Stool Testing for Colorectal Cancer Surveillance |
|
- Behavioral: Collection of stool sample
|
Observational |
|
- The Netherlands Cancer Institute
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Maastricht University Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- accuracy of molecular stool test (Cologuard) and FIT
- cost-effectiveness of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model
- life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model
- (and 3 more...)
|
4000 |
All |
50 Years to 75 Years (Adult, Senior) |
NCT02715141 |
M15MOC
NL52708.018.15 |
MOCCAS |
October 2015 |
July 2017 |
July 2017 |
March 22, 2016 |
June 20, 2016 |
|
- Nethelands Cancer Institute
Amsterdam, Noord-Holland, Netherlands
|
| 40 |
NCT03399188 |
Recruiting |
Fecal Microbiota Transplantation and Analysis of Fecal Microbiome in IBD Patients |
- Inflammatory Bowel Diseases
|
- Procedure: Fecal microbiome transplantation
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical remission
- Microbiome analysis by using relative abundance at phylum and genus level, beta diversity
- Clinical response using disease activity index
- (and 2 more...)
|
100 |
All |
7 Years to 80 Years (Child, Adult, Senior) |
NCT03399188 |
4-2017-0223 |
|
November 15, 2017 |
November 30, 2023 |
December 31, 2023 |
January 16, 2018 |
January 17, 2018 |
|
- Severance hospital
Seoul, Korea, Republic of
|
| 41 |
NCT02847481 |
Recruiting |
A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS |
|
- Procedure: fecal microbiota transplantation
- Drug: placebo fecal microbiota transplantation
- Procedure: FMT with antibiotic pre-treatment (v1)
- Procedure: FMT with antibiotic pre-treatment (v2)
|
Interventional |
Phase 1 |
- Anthony Lembo
- OpenBiome
- Beth Israel Deaconess Medical Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- stable engraftment of donor microbiota
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT02847481 |
2015P000211 |
|
May 2016 |
December 2018 |
May 2020 |
July 28, 2016 |
March 13, 2018 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
| 42 |
NCT03420482 |
Recruiting |
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy |
|
- Drug: Fecal Microbiota Transplant (FMT) oral capsules
- Drug: Placebo oral capsule
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- Center for Microbiome Informatics and Therapeutics
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Psychometric Hepatic Encephalopathy Score (PHES)
- Adverse events
- Stroop Test
- (and 3 more...)
|
30 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03420482 |
2017P002296 |
|
April 1, 2018 |
March 31, 2019 |
December 31, 2020 |
February 2, 2018 |
March 30, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 43 |
NCT02291523 |
Recruiting |
The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis |
|
- Biological: Fecal Microbial Transplant
|
Interventional |
Phase 1 |
- Children's Hospital Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary endpoint is disease remission based on PUCAI scores (<10).
- Secondary endpoints will include change in mucosal inflammation reflected on laboratory studies.
|
101 |
All |
7 Years to 21 Years (Child, Adult) |
NCT02291523 |
CHLA-16-00050 |
FMT_UC |
November 2016 |
November 2021 |
November 2023 |
November 14, 2014 |
November 25, 2016 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States
|
| 44 |
NCT03223792 |
Recruiting |
Acceptance Of A Partially-Hydrolyzed Infant Formula |
|
- Other: Control
- Other: Investigational
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Stool consistency measured by MJN stool consistency scale
- Stool frequency
- Formula acceptance measured by intake diary
- (and 3 more...)
|
100 |
All |
up to 300 Days (Child) |
NCT03223792 |
3389-1 |
|
August 21, 2017 |
April 2018 |
May 2018 |
July 21, 2017 |
October 3, 2017 |
|
- Birmingham Pediatric Associates
Birmingham, Alabama, United States - Southeastern Pediatric Associates
Dothan, Alabama, United States - Northwest Arkansas Pediatric Clinic
Fayetteville, Arkansas, United States - (and 8 more...)
|
| 45 |
NCT03078803 |
Recruiting |
Fecal Transplant for Crohn's Disease |
|
- Biological: Fecal Microbiota Transplant (FMT)
- Biological: Placebo
|
Interventional |
Phase 2 |
- University of Alberta
- University of Calgary
- McMaster University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical and Endoscopic Remission
- Clinical response
- Clinical remission
- (and 5 more...)
|
126 |
All |
18 Years and older (Adult, Senior) |
NCT03078803 |
66218 |
|
March 28, 2017 |
March 2020 |
March 2021 |
March 13, 2017 |
May 3, 2017 |
|
- University of Alberta
Edmonton, Alberta, Canada
|
| 46 |
NCT03026231 |
Not yet recruiting |
Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients |
|
- Biological: PRIM-DJ2727
- Drug: Placebo (for PRIM-DJ2727)
|
Interventional |
Phase 1
Phase 2 |
- The University of Texas Health Science Center, Houston
- Kelsey Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Microbiome Diversity in Fecal Samples s Indicated by the Shannon Diversity Index
- Microbiome Richness in Fecal Samples as Indicated by the Number of Taxonomies per Participant
- Most abundant Phylum in Fecal Sample
- (and 7 more...)
|
30 |
All |
45 Years to 70 Years (Adult, Senior) |
NCT03026231 |
UT-SPH/KRF FMT-2016-PD-01 |
|
July 15, 2017 |
December 15, 2019 |
December 15, 2019 |
January 20, 2017 |
April 20, 2017 |
|
- The University of Texas Health Science Center at Housotn
Houston, Texas, United States
|
| 47 |
NCT02127398 |
Recruiting |
Stool Transplants to Treat Refractory Clostridium Difficile Colitis |
- Clostridium Difficile Colitis
|
- Biological: fecal microbiota
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrent colitis due to Clostridium difficile
- Tolerability of oral fecal microbiota transplantation
- Safety of oral fecal microbiota transplantation
- (and 4 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02127398 |
Pro00053348 |
|
April 2016 |
April 2018 |
April 2018 |
April 30, 2014 |
May 9, 2017 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
| 48 |
NCT02897661 |
Recruiting |
Fecal Microbiota Transplantation Improves Nutritional State of Patients With Crohn's Disease |
|
- Procedure: FMT
- Drug: Metronidazole
- Dietary Supplement: EN
|
Interventional |
Phase 2
Phase 3 |
- The Second Hospital of Nanjing Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- changes in nutritional index
- changes in inflammation markers
- changes in inflammation index
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT02897661 |
NEU-CN-160814 |
|
August 2016 |
June 2017 |
December 2017 |
September 13, 2016 |
January 30, 2017 |
|
- Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
|
| 49 |
NCT02449174 |
Recruiting |
Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route |
|
- Biological: Frozen Microbiota
- Biological: Lyophilized Microbiota
|
Interventional |
Phase 1
Phase 2 |
- The University of Texas Health Science Center, Houston
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of participants who continue to have diarrhea and C. difficile toxin following fecal microbiota transplantation from a healthy donor
- Number of participants who develop obesity following fecal microbiota transplantation from a healthy donor
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02449174 |
HSC-SPH-14-0020 |
|
September 2014 |
December 2017 |
December 2017 |
May 20, 2015 |
November 17, 2016 |
|
- University of Texas Health Science Center at Housotn
Houston, Texas, United States
|
| 50 |
NCT02770326 |
Recruiting |
Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection |
- C. Difficile Infection
- Cancer
|
- Biological: Fecal Microbiota Transplantation (FMT)
|
Interventional |
Not Applicable |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate safety based the number of infections
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02770326 |
15-337 |
|
May 10, 2016 |
May 2018 |
May 2018 |
May 12, 2016 |
March 23, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
Create an RSS feed from your search for:
Download the search results for: